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Available online 28 September 2016Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum
concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovas-
cularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating
preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been
suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between
23 weeks + 0 days and 27 weeks +6 days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks
showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe
intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen satura-
tion targets were increased to 90–95%, due to national guidelines, whichmight have affected ROP rate and sever-
ity making increased IGF-I a weaker preventative factor for ROP.








Retinopathy of prematurity (ROP) is a potentially preventable
neurovascular disorder, which is estimated to make 20.000 infants
blind or severely visually impaired each year worldwide. In settings
with highly developed neonatal care, ROPmainly affects extremely pre-
term infants born before 28 gestationalweeks,whilewith less advanced
care,moremature infants becomeblind fromROP [1]. Control of oxygen
supplementation reduces severe ROP but optimal oxygenation targets
are still unknown. Postnatal bio-energetic failure with growth retarda-
tion is a universal phenomenon in very preterm infants [2] which is
associated with ROP and low circulating concentrations of IGF-I [3], an
anabolic hormone with mitogenic, differentiating, anti-apoptotic and
metabolic effects [4].
IGF-I exerts its actions in endocrine, paracrine and autocrine man-
ners through binding to the IGF-I receptor and with substantially less
afﬁnity to the insulin receptor. IGF-I plays many roles, which differ
depending on factors such as source [5], target cell type and develop-
mental stage [6]. Six binding proteins (IGFBP) control IGF-I actions. Ap-
proximately 80% of circulating IGF-I is bound to IGFBP-3which together
with an acid-labile subunit (ALS), prolongs the half-life andmaintains a
reservoir of IGF-I in the circulation [7,8]. IGFBP-1 increases with fastingtröm).
. This is an open access article underand hypoxia and restrains growth by decreasing IGF-I bioavailability [9].
Growth hormone regulates hepatic IGF-I production in children and
adults but not in the fetus. During gestation, circulating fetal IGF-I
concentrations are dependent on nutrient supply from the mother
and increase during the third trimester [10]. At term birth, higher cord
serum IGF-I concentrations are associated with increased fetal size
and fat mass [11]. Circulating IGF-I is mainly derived from the liver
but virtually all human fetal tissues express IGF-I from an early stage
[12]. Amniotic ﬂuid contains higher IGF-I concentrations than cord
blood during gestation or at delivery and is swallowed by the fetus
[13]. It is not clear whether placenta-derived IGF-I is secreted into the
fetal circulation [14]. Little is known about the roles of locally synthe-
sized versus circulating IGF-I. However, circulating IGF-I levels are
thought to provide information about the state of the organism as a
whole [15].
IGF-I expression in the central nervous system to which the retina
belongs is highly developmentally regulated and mainly localized in
large projection neurons during a brief period of late development
[16]. In the maturing rat retina IGF-I mRNA is concentrated in the gan-
glion cell layer during the ﬁrst weeks after birth when retinal vascular-
ization takes place and then rapidly decreases [17]. In neonatal mice,
IGF-I is expressed throughout the retina while the IGF-I receptor is
expressed predominantly in photoreceptors and blood vessels. IGFBP-
3 expression increases N5-fold in neovascular tufts in oxygen-induced
retinopathy during hypoxia-driven neovascularization [18].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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proximately 10 ng/mL compared to N50 ng/mL in utero at postmenstrual
age (PMA) 23–30 weeks (Fig. 1) [10,19–22]. Persistent low serum IGF-I
levels are associated with poor general growth and poor brain growth
as well as neonatal morbidities such as intraventricular hemorrhage
(IVH), retinopathy of prematurity (ROP), bronchopulmonary dysplasia
(BPD) and necrotizing enteritis (NEC) [23]. We will review IGF-I in rela-
tion to normal retinal development and ROP and the possible role of IGF-I
supplementation in the prevention of ROP.
2. Retinal vascularization and classiﬁcation of ROP
Proper vascularization is essential for the supply of oxygen, nutrients
and other factors to developing tissues. Since blood vessels in the eye
are available for direct inspection with non-invasive methods such as
indirect ophthalmoscopy and the retina may be severely affected by
very preterm birth, much research has focused on retinal vasculariza-
tion. Endothelial cells, which play a key role in both vasculogenesis
and angiogenesis, produce IGF-I. In cultures of bovine retinal endotheli-
al cells (BRECs), the production of IGF-I is greatly increased in a hypoxic
environment [24]. IGF-I promotes glucose uptake in processes depen-
dent on protein kinase C (PKC) and phosphatidylinositol-3 kinase
(PI3K) and stimulates cell proliferation [25]. IGF-I-stimulated glucose
transport in BRECs requires activation of mitogen activated protein
kinase (MAPK), which is upstream of PKC but independent of PI3K in
mediating the effect of IGF-I on endothelial cells [26]. However, when
BRECs are exposed to high glucose concentrations they become insensi-
tive to IGF-I at least in part due to reduced activation of the p42/44
MAPK pathway [27]. Hypoxia is a major angiogenic stimulus which in-
creases transcription of vascular endothelial growth factor (VEGF)
mRNA. IGF-I may also increase VEGF-1 synthesis [28]. Minimal levels
of IGF-I are required for VEGF activation of pathways promoting retinal
vascular endothelial cell proliferation and survival [29]. Impaired
normal neonatal angiogenesis after preterm birth followed by tissue
hypoxia and nutrient insufﬁciency driving proliferative angiogenesis is
a hallmark of ROP but might apply to BPD [30] and encephalopathy of
prematurity [31] as well.Fig. 1.Normal intrauterine IGF-I concentrations obtained from the umbilical cordwith cordocen
of matched postmenstrual ages (red dots) (20−22).During normal human retinal development, blood vessels grow
from the optic disk at around 14 gestational weeks and reach the pe-
riphery at term. Experimental studies to elucidate mechanisms behind
ROP are based on studies in oxygen induced retinopathy (OIR) in ro-
dents i.e. mice and rats in which retinal vascularization normally takes
place during the ﬁrst weeks of extrauterine life. Normal vessel growth
is stimulated by VEGF and other factors in response to “physiologic hyp-
oxia” appearing in front of the vessels when the neural retina matures
[32].
Retrolental ﬁbroplasia, the end stage of ROP, was ﬁrst described by
Terry in 1942 in blind prematurely born infants exposed to high oxygen
levels in closed incubators. Fibrovascular tissue containing the detached
retina was seen behind the crystalline lens. Earlier stages of ROP were
later identiﬁed and classiﬁed according to vascular changes visible
with ophthalmoscopy. At very preterm birth, only the central part of
the retina is vascularized and the periphery remains avascular. The
ﬁrst sign of ROP is a sharp demarcation line (stage 1) which may in-
crease in volume to become a ridge (stage 2) at the border between
vascularized and avascular retina. These changes often regress sponta-
neously, but inmore severe cases, progress to stage 3with uncontrolled
neovascularization at the ridge,which in turnmay regress or progress to
partial (stage 4) and total (stage 5) retinal detachment (Fig. 2).
Engorgement and tortuosity of central retinal vessels is an ominous
sign called plus disease. In ROP classiﬁcation, the retina is divided into
three zones where zone I is the most central and zone III the most
peripheral. In cases with central ROP and a large avascular retinal area,
aggressive posterior ROP (APROP), a rapidly progressing severe form
with plus disease but without distinct progression through stages,
may occur [33]. Electro-physiologic studies in ROP patients have dem-
onstrated that not only blood vessels but also neural cells such as retinal
photoreceptors are affected in early stages of ROP [34].
The neonatal period of the very pretermnewborn is characterized by
problems adapting to extra-uterine life, energy deﬁciency, infections,
hyperglycemia, low serum IGF-I and un-physiologic oxygenation with
periods of hyperoxia as well as hypoxia. ROP is a two phase disease. In
the ﬁrst phase blood vessel growth is arrested and parts of already
formed vessels regress, leaving thematuring peripheral retina avasculartesis over 18 to 42weeks of gestation (GA) (n=174) (10,19) compared to preterm infants
Fig. 2. Stages of ROP. Stage 1—Demarcation line between vascular and avascular retina. Stage 2—Ridge. Stage 3—Extraretinal neovascularizations at the ridge. The abnormal blood vessels
grow toward the center of the eye instead of following their normal growth pattern along the surface of the retina. When infants have a certain degree of Stage 3 and “plus disease”
develops, treatment is considered. “Plus disease”means that the blood vessels of the retina have become enlarged and twisted, indicating a worsening of the disease. Stage 4 —Partially
detached retina. Stage 5— Completely detached retina and the end stage of the disease. (Painting by Ann-Soﬁe Petersson).
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not been properly deﬁned and onemay consider the appearance of any
ROP stage as the beginning of phase II, (whichwewill do in this review)
or the onset of the neovascularization of stage 3 exclusively. Phase I
extends from birth to around 30–34 weeks when the ocular character-
istics of ROP are ﬁrst seen. Efforts to reduce ROP include prevention of
blood vessel loss and promotion of normal retinal vessel growth in the
ﬁrst phase of the disease and treatment i.e. measures tomake neovascu-
larization regress in phase II to prevent retinal detachment. Thus, inter-
vention approaches are diametrically different in the two phases. In
addition, prevention of progression from mild to severe ROP using oral
propranolol has the potential to reduce severe ROP but safety is a
serious concern [35].3. Current ROP treatment
Current treatment addresses neovascularization in advanced ROP to
prevent retinal detachment and blindness. Ablation of the avascular and
hypoxic retina (which produces many angiogenic factors such as VEGF)
peripheral to the ridge by laser or cryotherapy constitutes the only
evidence-based treatment. However, intra-vitreal injection of anti-
VEGF antibodies is gaining popularity despite being poorly investigated
regarding dosage and long-term safety. Compared to treatment of
neovascular retinal disease in mature adults, suppressing vascular
growth in the vasoproliferative phase must take into account the need
for allowing normal angiogenesis in the retina but also in other organs
in a fast growing immature preterm infant. Anti-VEGF-antibodies es-
cape the eye and stay in the circulation for weeks to months and reduce
circulating VEGF with unknown effects on brain, kidneys, lungs and
other organs [36].Fig. 3.Major path4. Current ROP prevention
When unrestricted oxygen supplementation was initially identiﬁed
as a cause of retinopathy in preterm infants in the mid-1900s, oxygen
supply was severely curtailed and the incidence of retrolental ﬁbroplasia
decreased but at the cost of increased mortality and cerebral palsy [37].
The optimal oxygenation of preterm infants is still unknown. Oxygen
toxicity may also vary by postnatal age, which has not been addressed
in clinical trials. Lately ﬁve randomized controlled trials report that a
higher oxygen saturation (91–95%) target range for babies regardless of
gestational age at birth is associated with less mortality than a lower
(85–89%) [38]. However, the quality of evidence for this estimate of effect
was later found to be low [39]. Based on these studies, an oxygen satura-
tion target range of 91–95% is now used in many neonatal intensive care
units. Aggressive parenteral nutritionmay decrease the incidence of total
ROP but not severe ROP, and supplementation of vitamin A, E, and breast
milk feeding have been shown to be beneﬁcial but only in observational
studies [40]. Interestingly, serum IGF-I concentrations correlate with
growth (change in weight standard deviation score) but not with nutri-
ent intake until 30 weeks PMA, Fig. 3 [41].5. IGF-I in the two phases of ROP
IGF-I is essential for normal neurovascular development and low
serum concentrations in the ﬁrst phase of ROP, concomitant with the
growth retardation phase in very preterm infants, correlate with later
severe disease. Fromaround 30weeks PMA, catchup growth commonly
occurs and uncontrolled neovascularizationmay ensuewhen IGF-I con-
centrations increase, since IGF-I also plays a key role in pathologic neo-
vascularization [42]. Pharmacologic inhibition or genetic deletion of theways of ROP.
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larization [43,44].
6. Serum IGF-I levels in prediction of ROP
In preterm infants a strong correlation between low serum IGF-I
levels during the ﬁrst weeks of life and later ROP development was
found and it was suggested that neonatal serum IGF-I levels might be
used to predict which infants were at increased risk of developing
severe ROP [29]. If such predictions were possible, those at low risk
could be spared some eye examinations and those at high risk could
get extra attention. ROP screening programs generally include infants
based on gestational age (GA) at birth and/or birth weight (BW). Only
a small fraction of these infants, who are subjected to repeat painful
and stressful eye examinations, need treatment. In Sweden, infants
born before 32 gestational weeks had on average 5.2 eye examinations
and only 4.4% of the infants were treated for severe ROP [45]. Based on
longitudinal weight and IGF-I development after birth the algorithm
Weight IGF-I Neonatal ROP (WINROP)wasdeveloped [46]. At validation
in Sweden, WINROP identiﬁed all infants needing treatment weeks to
months before they were diagnosed with proliferative ROP [47]. The
strong correlation between serum IGF-I and weight gain made it
possible to use WINROP based on weight development only, thus
avoiding blood sampling [48].WINROP has now been validated in thou-
sands of infants in many different countries with high sensitivity in
settings with advanced neonatal care [49] but lower sensitivity when
care is less developed [50]. We ﬁnd it valuable as an adjunct to general
screening.
7. IGF-I intervention in prevention of ROP
An old report on the regression of diabetic retinopathy in a patient
with pituitary infarction [51] prompted an investigation of the role of
the GH-IGF-I axis in a mouse model of ischemic retinopathy. Neovascu-
larizationwas suppressedwith inhibition of theGH-IGF-I axis and itwas
concluded that systemic inhibition or GH or IGF-I might prevent ROP
[52]. However, inhibition of the GH-IGF-I axis results in a dwarf pheno-
type. Since the neovascular phase of ROP is preceded by a ﬁrst phase of
impaired retinal vessel growth, it was speculated and conﬁrmed that se-
vere ROP is associated with low circulating IGF-I concentrations during
this phase. It was further suggested that early postnatal supplementa-
tion with IGF-I to normal fetal levels might prevent ROP [23,29].
In a commonly used OIR mouse model, mice pups are exposed to
75% oxygen from postnatal day (P) 7 to P12 and thereafter kept in
room air. At P17 extensive neovascularization occurs in all mice [53].
Using this model, IGF-I knockout mice have retarded retinal vessel
growth and low IGF-I suppresses VEGF-induced survival and prolifera-
tion signaling in retinal endothelial cells [29].
In an experimental study of IGF-I supplementation in OIR, neonatal
mice in normal and larger litters were exposed to hyperoxia. Neonatal
mice in larger litters weigh less, have lower levels of circulating IGF-I
and develop more proliferative retinopathy than mice pups in normal
litters. Treatment with a single intraperitoneal dose of rhIGF-I as well
as of placebo (saline) is associated with N90% mortality in mice pups
of larger litters precluding the study of IGF-I supplementation effects
in that group. Pups of normal litters that received recombinant human
(rh) IGF-I on day 4 weighed more, had higher endogenous IGF-I levels,
matured faster and had less retinopathy than thosewho received place-
bo [54].
Adult fresh frozen plasma contains varying amounts of IGF-I. For a
better understanding of the pharmacokinetics of IGF-I and IGFBP3 in
preterm infants two studies were performed. One evaluated the effects
of transfusing fresh frozen plasma and the other of infusing rhIGF-I/
IGFBP-3 over a period of three hours on serum IGF-I and IGFBP-3 levels.
Fresh frozen plasma increased serum concentrations of IGF-I and IGFBP-
3 but the half-life of IGF-I in serum after plasma infusion was short(≈3 h compared to≈17 h in adults [55,56]). After intravenous infusion
for 3 h of the drug mecasermin rinfabate, an equimolar preparation of a
recombinant protein complex of rhIGF-I and IGFBP-3, the IGF-I half-life
was even shorter (b1 h) suggesting that administration of IGF-I to pre-
term children should be performed via continuous intravenous infusion
[57].
In a later study, infusion of an equimolar preparation of rhIGF-I/rh
IGFBP-3 (Premiplex) in doses ranging between 21 and 111 μg/kg/24 h
during the ﬁrst week of life increased serum IGF-I concentration to the
lower range of the normal intrauterine range without any evident
adverse effects [58].
A multicenter phase 2 study (IGF-I IGFBP3 prevention of Retinopa-
thy of Prematurity, ClinicalTrials.gov Identiﬁer: NCT01096784) has
recently been completed by Shire et al. One-hundred-twenty-one in-
fants with GA between 23 weeks + 0 days and 27 weeks +6 days
were treated with mecasermin rinfabate until post-menstrual age
30 weeks. Results have not been published yet, but in a press release
by the company, no effect was reported on ROP. However, treated in-
fants had a 53% reduction in incidence of severe BPD compared to un-
treated infants. In addition, an 89% reduction was found in those who
achieved target serum IGF-I concentrations compared to untreated in-
fants. Data also showed a 44% reduction in the incidence of severe IVH
(grade III and IV) in treated patients and a 64% reduction in those with
serum IGF-I within target range.
Are there any plausible explanations for the lack of effect of IGF-I
supplementation on ROP in this study?
One explanation may involve oxygen, the best known risk factor for
ROP. During this phase 2 study, the oxygen saturation (SpO2) target
level was 91–95%. To our knowledge, compliance with this target
range was not investigated. The neonatal intensive care unit of our hos-
pital, Sahlgrenska University Hospital in Gothenburg Sweden, did not
participate in this study, but in 2014 the new higher SpO2 target range
of 91–95% was implemented. After that change, the number of infants
who needed treatment for ROP doubled. In addition, WINROP, which
prior to the increase identiﬁed close to 100% of infants who would
later develop ROP now failed to identify approximately half of the in-
fants that were later treated for ROP (manuscript in preparation) indi-
cating that perhaps factors related to growth may be less important
with this new oxygenation saturation target of SpO2 within 91–95%.
Manley et al. have also reported increased rates and severity of ROP
after implementation of this higher SpO2 target range [59]. They specu-
lated that a higher target range increases the tolerance by clinical staff to
saturations above this range. In addition, low compliance with oxygen
targetingwith upper alarm limits inappropriately set too high and difﬁ-
culties in maintaining saturation below the upper limit are common
[60–63]. However, other explanations for the outcome of the study are
possible.
This implies that in studies concerning risk factors for ROP, treat-
ment with oxygen and monitoring thereof has to be optimized. A very
important factor is compliance with saturation targets. It is crucial that
alarm limits are set close to target limits and that the staff is well trained
and sufﬁcient in number, and that there are well documented strategies
for oxygen titration. Automated adjustment of the fraction of inspired
oxygen may improve SpO2 targeting across different SpO2 ranges [61,
64]. A reduced incidence of ROP has been reported after implementa-
tion of meticulous oxygen control [60,65].
8. In conclusion
There is at present no evidence supporting an effect of IGF-I supple-
mentation in very preterm infants for the prevention of ROP, although a
preventive effect has been found for severe BPD and IVH. Oxygen treat-
ment is a strong risk factor for ROP, and oxygen saturation is often poor-
ly controlled. If this was the case in the phase 2 study evaluating effects
of IGF-I supplementation on ROP, it is possible that future studies with
strict oxygen control may generate different results.
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